Levoleucovorin
Fusilev, Khapzory (levoleucovorin) is a small molecule pharmaceutical. Levoleucovorin was first approved as Fusilev on 2008-03-07.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Fusilev, Khapzory (generic drugs available since 2015-03-09)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Levoleucovorin, Khapzory, Acrotech Biopharma | |||
| 11541012 | 2039-03-25 | DP | |
Clinical
Clinical Trials
152 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 6 | 4 | 11 | 5 | 26 |
| Allergic rhinitis | D065631 | J30.9 | — | 3 | 6 | 11 | 2 | 22 | |
| Healthy volunteers/patients | — | 12 | — | 1 | 1 | 2 | 16 | ||
| Allergic rhinitis perennial | D012221 | EFO_1001417 | J30.89 | — | — | 7 | 8 | — | 15 |
| Rhinitis | D012220 | EFO_0008521 | J31 | 3 | 1 | 3 | 2 | 2 | 11 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 6 | — | — | 3 | — | 9 |
| Urticaria | D014581 | EFO_0005531 | L50 | — | — | 3 | 4 | 1 | 8 |
| Chronic urticaria | D000080223 | L50.8 | — | — | 3 | 5 | — | 8 | |
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | 3 | 3 | — | 6 |
| Pruritus | D011537 | HP_0000989 | L29 | — | — | 1 | 3 | 1 | 5 |
Show 10 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | — | 1 | 5 | — | — | 5 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | 1 | — | 1 | — | — | 2 |
| Vasomotor rhinitis | D012223 | EFO_0007533 | J30.0 | — | — | 1 | — | 1 | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | 1 | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 1 | — | — | 1 | |
| Head and neck neoplasms | D006258 | — | — | 1 | — | — | 1 | ||
| Esophageal neoplasms | D004938 | C15 | — | — | 1 | — | — | 1 | |
| Lung neoplasms | D008175 | C34.90 | — | — | 1 | — | — | 1 | |
| Uterine cervical neoplasms | D002583 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | 1 | — | — | — | 1 | ||
| Neuromyelitis optica | D009471 | EFO_0004256 | G36.0 | 1 | 1 | — | — | — | 1 |
| Cough | D003371 | HP_0012735 | R05 | — | 1 | — | — | — | 1 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatitis | D011472 | EFO_0003830 | N41 | 1 | — | — | — | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | — | — | — | — | 1 |
| Fasting | D005215 | EFO_0002756 | 1 | — | — | — | — | 1 | |
| Larva migrans | D007815 | EFO_0007391 | B76.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cognition | D003071 | EFO_0003925 | — | — | — | — | 1 | 1 | |
| Actinic keratosis | D055623 | L57.0 | — | — | — | — | 1 | 1 | |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LEVOLEUCOVORIN |
| INN | calcium levofolinate |
| Description | Folinic acid, also known as leucovorin, is a medication used to decrease the toxic effects of methotrexate and pyrimethamine. It is also used in combination with 5-fluorouracil to treat colorectal cancer and pancreatic cancer, may be used to treat folate deficiency that results in anemia, and methanol poisoning. It is taken by mouth, injection into a muscle, or injection into a vein.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc(=O)c2c([nH]1)NC[C@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O |
Identifiers
| PDB | — |
| CAS-ID | 68538-85-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1908841 |
| ChEBI ID | 63606 |
| PubChem CID | 6006 |
| DrugBank | DB00650 |
| UNII ID | 778XL6VBS8 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Fusilev - Spectrum Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 142 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,319 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more